| Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma (NCT02082405) | Case Comprehensive Cancer Center | 2015-04-01 |
| Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT02224729) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-08-25 |
| Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma (NCT01954784) | Case Comprehensive Cancer Center | 2013-10-07 |
| Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (NCT01812720) | Mayo Clinic | 2013-08-01 |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (NCT01849783) | Margarida Magalhaes-Silverman | 2013-04-04 |
| Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT01816971) | University of Chicago | 2013-01-01 |
| Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (NCT01676961) | NYU Langone Health | 2013-01-01 |
| Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant (NCT01706666) | Mayo Clinic | 2012-12-07 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients (NCT01653106) | Ohio State University Comprehensive Cancer Center | 2012-04-01 |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant (NCT01534143) | Barbara Ann Karmanos Cancer Institute | 2012-02-01 |
| Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma (NCT01518465) | University of Southern California | 2012-01-09 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma (NCT02037256) | Barbara Ann Karmanos Cancer Institute | 2011-07-01 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma (NCT01057225) | Mayo Clinic | 2010-03-01 |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant (NCT00998049) | Mayo Clinic | 2009-12-01 |
| Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (NCT00693433) | National Cancer Institute (NCI) | 2008-12-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00719901) | National Cancer Institute (NCI) | 2008-07-01 |
| Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant (NCT00619684) | Fred Hutchinson Cancer Center | 2008-02-01 |
| Sunitinib in Treating Patients With Relapsed Multiple Myeloma (NCT00514137) | National Cancer Institute (NCI) | 2007-09-01 |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone (NCT00522392) | National Cancer Institute (NCI) | 2007-09-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma (NCT00398515) | National Cancer Institute (NCI) | 2007-03-01 |
| Aflibercept for Relapsed Multiple Myeloma (NCT00437034) | National Cancer Institute (NCI) | 2007-01-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (NCT00112723) | National Cancer Institute (NCI) | 2005-12-01 |
| Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00310024) | National Cancer Institute (NCI) | 2005-11-01 |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma (NCT00243035) | National Cancer Institute (NCI) | 2005-08-01 |
| Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma (NCT00217438) | Fred Hutchinson Cancer Center | 2005-07-01 |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma (NCT00112827) | City of Hope Medical Center | 2004-11-01 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function (NCT00118170) | National Cancer Institute (NCI) | 2004-10-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00079456) | National Cancer Institute (NCI) | 2004-02-01 |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT00075881) | National Cancer Institute (NCI) | 2004-01-01 |
| Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant (NCT00182663) | Fred Hutchinson Cancer Center | 2003-06-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00047203) | National Cancer Institute (NCI) | 2002-09-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma (NCT00006244) | Fred Hutchinson Cancer Center | 2000-02-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma (NCT00003954) | Fred Hutchinson Cancer Center | 1999-03-01 |
| Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma (NCT00003196) | Fred Hutchinson Cancer Center | 1997-09-01 |
| Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation (NCT00002787) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 1996-03-01 |
| Vaccine Therapy in Treating Patients With Multiple Myeloma (NCT00019097) | National Cancer Institute (NCI) | 1995-07-01 |
| Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma (NCT00002556) | National Cancer Institute (NCI) | 1994-07-01 |
| Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00085345) | Oncotherapeutics | |